ALPN - Starting To Clawback April Losses - Analyst's Bullish

NASDAQ:ALPN   Alpine Immune Sciences, Inc
Alpine Immune Sciences , Inc. , formerly Nivalis Therapeutics, Inc. , is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

15.61K 07/15/19 (Short Interest)

P/E Current

P/E Ratio (with extraordinary items)

Average Recommendation: BUY

Average Target Price: 13.50

Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:

2) Follow our Telegram Channel @

3) Join our LIVE CHAT on Discord @

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.